Over the past year, a robust body of evidence has emerged from the QWINT phase 3 clinical trial programme (QWINT-1 to QWINT-4 in type 2 diabetes and QWINT-5 in type 1 diabetes), collectively demonstrating that efsitora is an effective alternative to conventional daily insulins. Here, INS is linked to type 2 diabetes mellitus.